Painful Diabetic Peripheral Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Painful Diabetic Peripheral Neuropathy Market Outlook
Thelansis’s “Painful Diabetic
Peripheral Neuropathy Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Painful
Diabetic Peripheral Neuropathy treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Painful
Diabetic Peripheral Neuropathy Overview
Painful
Diabetic Peripheral Neuropathy characteristically presents with a tingling
sensation, numbness, burning, excruciating stabbing type of pain, sometimes
intractable. It may be associated with paraesthesia and hyperesthesia coupled
with deep aching in the feet or hands. Poor glycaemic control is a major risk
factor for the development of diabetic neuropathy. It has been observed that an
estimated 50% of patients develop Painful Diabetic Peripheral Neuropathy 25
years after the initial diagnosis of diabetes mellitus. The prevalence of PDN
ranges from 10% to 20% of patients with diabetes, and in those with diabetic
neuropathy, it ranges from 40% to 50%. The underlying mechanism for the
generation of pain is hyperexcitability in primary afferent nociceptors, which
occurs due to damage to peripheral nerves. This in turn, leads to
hyperexcitability in central neurons and the generation of spontaneous impulses
within the axon and the dorsal root ganglion of these peripheral nerves.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment